ClinicalTrials.gov
public full text
Public Domain
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC#394758
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients#208413
- CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy#898097
- Vemurafenib and White Blood Cell Therapy for Advanced Melanoma#668830
- Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma#969001
Record · ID 994547
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive